Esperion to Participate in The 2026 Citizens Life Sciences Conference

Company Overview - Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing innovative therapies for cardiometabolic and rare/orphan diseases [2] - The company markets two oral, once-daily, non-statin therapies aimed at patients struggling to maintain low-density lipoprotein cholesterol (LDL-C) levels and at risk of cardiovascular disease [2] Market Position and Strategy - Esperion has a broad U.S. commercial infrastructure and has received global approvals in over 40 countries, positioning itself as a partner-of-choice for global innovators seeking U.S. market access through various collaboration opportunities [3] - The company is advancing its expertise in ACLY biology to build a diversified pipeline of novel product candidates, including treatments for Primary Sclerosing Cholangitis and renal diseases [3] Upcoming Events - Esperion will participate in the webcasted 2026 Citizens Life Sciences Conference on March 11, 2026, at 8:25 a.m. ET, with a live webcast accessible on its investor and media section [1]